The 14th China Health Forum, hosted by People's Daily and Health Times, was held in Beijing. Lifetech Cardio’s 8301 temporary pacemaker was awarded the "Top 10 Medical Devices Award”, after undergoing a rigorous evaluation process by multiple authorities.

The forum is one of the earliest and most authoritative conferences in the field of health and wellness in China. The ranking process started on 7 October, 2021, and spanned over seven months. During this time, various organisational bodies, such as Ranking Advisory Committee, Academic Committee, Ranking Work Group, were established to to develop the criteria for candidate selection. The process involved soliciting opinions through methods such as expert recommendations, industry interviews, and data verification. Followed the evaluation criteria, 8301 temporary pacemaker from Lifetech Cardio was included as a candidate in the ranking list.

To compete with many top medical devices in the industry, this is undoubtedly an intense competition. After an online public vote, and through the rigorous evaluation by hundreds of experts from the Ranking Advisory Board and Academic Committee, 8301 TPM stood out and finally won the award. The device is not only developed independently by Lifetech Cardio, but also fills the domestic gap in China.



In the award citation, 8301, the first temporary pacemaker developed in China, was recognised as having achieved "a significant breakthrough from a functional device to an intelligent one". What stands out is that the 8301 not only combines the functions of temporary pacing and pacing analysis but also introduces innovative features like intracavitary electrocardiograms (ECG) and pacing percentages. Such features are convenient for doctors to observe the current of injury and provide accurate data support for precise device removal, offering much convenience for both doctors and patients.
In terms of intellectual property, Lifetech Cardio has applied for seven patents related to the 8301 pacemaker which involves many core technologies. Launched for one year, 8301 has been applied in more than 100 hospitals in China, gaining excellent clinical feedback.

